GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Hagit Eldar-Finkelman(Tel Aviv University), Ana Martı́nez(Consejo Superior de Investigaciones Científicas)
Cited by 348
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action
|Proceedings of the National Academy of Sciences|1997|313
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293